

## Publication List Priv.-Doz. Dr. Mazda Adli (January 25, 2019)

Total Impact Factor: 571.583, Hirsch Factor: 32

### Content:

- A. Original Papers (First or Senior Authorships)
- B. Co-Authorships
- C. Reviews
- D. Comments
- E. Other Publications (not peer-reviewed)
- F. Editor
- G. Book Chapters

### A. Original Papers (First or Senior Authorships):

1.	Bopp SK*, Heilbronner U*, Schlattmann P, Mühleisen TW, Bschor T, Richter C, Steinacher B, Stamm TJ, Merkl A, Herms S, Köhler S, Sterzer P, Hellweg R, Heinz A, Cichon S, Lang UE, Schulze TG, Adli M*, Ricken R*. Leptin gene polymorphisms are associated with weight gain during lithium augmentation in patients with major depression. <i>Eur Neuropsychopharmacol</i> , 2018. Dec .006	IMPACT FACTOR 4.129	Perzentil -
2.	Dimitrov A, Veer IM, Kleeblatt J, Seyfarth F, Roenneberg T, Ising M, Uhr M, Keck ME, Kramer A, Berger M, von Koch L, Walter H, Adli M (2018). Chronotype is associated with psychological well-being depending on the composition of the study sample. <i>J Health Psychol</i> . 2018 Jan 1:1359105317751618.	IMPACT FACTOR 2.182	Perzentil -
3.	Ricken R, Wiethoff K, Reinhold T, Stamm TJ, Baghai TC, Fisher R, Seemüller F, Brieger P, Cordes J, Laux G, Hauth I, Möller HJ, Heinz A, Bauer M, Adli M (2018). A standardized stepwise drug treatment algorithm for depression reduces direct treatment costs in depressed inpatients - Results from the German Algorithm Project (GAP3). <i>J Affect Disord</i> . 228:173-177.	IMPACT FACTOR 3.432	Perzentil -
4.	Ricken R, Busche M, Schlattmann P, Himmerich H, Bopp S, Bschor T, Richter C, Stamm TJ, Heinz A, Hellweg R, Lang UE, Adli M (2018). Cytokine serum levels remain unchanged during lithium augmentation of antidepressants in major depression. <i>J Psychiatr Res</i> . 96:203-208.	IMPACT FACTOR 4.183	Perzentil -
5.	Ricken R, Bopp S, Schlattmann P, Himmerich H, Bschor T, Richter C, Elstner S, Stamm TJ, Schulz-Ratei B, Lingesleben A, Reischies FM, Sterzer P, Borgwardt S, Bauer M, Heinz A, Hellweg R, Lang UE, Adli M (2017). Ghrelin Serum Concentrations Are Associated with Treatment Response During Lithium Augmentation of Antidepressants. <i>Int J Neuropsychopharmacol</i> . 20(9):692-697.	IMPACT FACTOR 4.712	Perzentil 16,3
6.	Adli M, Wiethoff K, Baghai TC, Fisher R, Seemüller F, Laakmann G, Brieger P, Cordes J, Malevani J, Laux G, Hauth I, Möller HJ, Kronmüller KT, Smolka MN, Schlattmann P, Berger M, Ricken R, Stamm TJ, Heinz A, Bauer M (2017). How Effective Is Algorithm-Guided Treatment for Depressed Inpatients? Results from the Randomized Controlled Multicenter German Algorithm Project 3 Trial. <i>Int J Neuropsychopharmacol</i> . 20(9):721-730.	IMPACT FACTOR 4.712	Perzentil 24,2
7.	Ricken R, Bopp S, Schlattmann P, Himmerich H, Bschor T, Richter C, Stamm TJ, Bauer F, Heinz A, Hellweg R, Lang UE, Adli M (2016). Leptin serum concentrations are associated with weight gain during lithium augmentation. <i>Psychoneuroendocrinology</i> . 71:31-35.	IMPACT FACTOR 4.944	Perzentil 2
8.	Stamm TJ, Rampp C, Wiethoff K, Stingl J, Mössner R, O Malley G, Ricken R, Seemüller F, Keck M, Fisher R, Gaebel W, Maier W, Möller HJ, Bauer M, Adli M (2016). The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with	IMPACT FACTOR 3.898	Perzentil

	remission in patients with major depression. <i>J Psychopharmacol.</i> 30(1):40-7.		77,7
9.	Köhler S, Wiethoff K, Ricken R, Stamm T, Baghai TC, Fisher R, Seemüller F, Brieger P, Cordes J, Malevani J, Laux G, Hauth I, Möller HJ, Zeiler J, Heinz A, Bauer M, <u>Adli M</u> (2015). Characteristics and differences in treatment outcome of inpatients with chronic vs. episodic major depressive disorders. <i>J Affect Disord.</i> 173: 126-33.	IMPACT FACTOR 3.710	Perzentil 55
10.	Stamm TJ, Becker D, Sondergeld LM, Wiethoff K, Hiemke C, O'Malley G, Ricken R, Bauer M, <u>Adli M</u> (2014). Prediction of antidepressant response to venlafaxine by a combination of early response assessment and therapeutic drug monitoring. <i>Pharmacopsychiatry.</i> 47(4-5): 174-9.	IMPACT FACTOR 2.168	Perzentil 23,9
11.	Stamm TJ, Stingl J, Wiethoff K, Ricken R, Heinz A, Bauer M, O'Malley G, <u>Adli M</u> (2013). Depression with psychotic features is influenced by the polymorphism of the serotonin transporter gene. <i>J Affect Disord.</i> 151: 605-610.	IMPACT FACTOR 3.383	Perzentil 24,1
12.	Ricken R*, <u>Adli M*</u> , Lange C, Krusche E, Stamm TJ, Gaus S, Koehler S, Nase S, Bschor T, Richter C, Steinacher B, Heinz A, Rapp MA, Borgwardt S, Hellweg R, Lang UE (2013). Brain-derived neurotrophic factor serum concentrations in acute depressive patients increase during lithium augmentation of antidepressants. <i>J Clin Psychopharmacol.</i> 33(6): 806-9.	IMPACT FACTOR 3.761	Perzentil 58,4
13.	Lange C, Zschucke E, Ising M, Uhr M, Birmaher B, <u>Adli M</u> (2013). Evidence for a normal HPA axis response to psychosocial stress in patients remitted from depression. <i>Psychoneuroendocrinology.</i> 38(11): 2729-36.	IMPACT FACTOR 5.591	Perzentil 59,2
14.	Ricken R, Wiethoff K, Reinhold T, Schietch K, Stamm T, Kiermeir J, Neu P, Heinz A, Bauer M, <u>Adli M</u> (2011). Algorithm-guided treatment of depression reduces treatment costs - Results from the randomized controlled German Algorithm Project (GAPII). <i>J Affect Disord.</i> 134:249-256.	IMPACT FACTOR 3.740	Perzentil 25,7
15.	Sterzer P, Hilgenfeldt T, Freudenberg P, <u>Adli M</u> (2011). Unconscious emotional information processing in patients with major depressive disorder. <i>Psychol Med.</i> 5: 1-10.	IMPACT FACTOR 5.012	Perzentil 60,2

## B. Co-Authorships:

16.	Dimitrov A, Schaake J, Ligdorf A, Oei NYL, Adli M, Walter H, Veer IM (2018). Natural sleep loss is associated with lower mPFC activity during negative distracter processing. <i>Soc Cogn Affect Neurosci.</i> Submitted on 10 July 2018.	IMPACT FACTOR 3.500	Perzentil -
17.	Schennach R, Obermeier M, Spellmann I, Seemüller F, Musil R, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Bauer M, <u>Adli M</u> , Zeiler J, Bender W, Kronmüller T, Ising M, Brieger P, Maier W, Lemke MR, Rüter E, Klingberg S, Gastpar M, Möller H, Riedel M (2018). Remission in schizophrenia - what are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression. <i>Schizophr Res.</i> Submitted on 12 May 2018.	IMPACT FACTOR 3.986	Perzentil 2,0
18.	Reinbold CS, Forstner AJ, Hecker J, Fullerton JM, Hoffmann P, Hou L, Heilbronner U, Degenhardt F, <u>Adli M</u> , Akiyama K, Akula N, Ardaur R, Arias B, Backlund L, Benabarre A, Bengesser S, Kumar Bhattacharjee A, Biernacka JM, Birner A, Marie-Claire C, Cervantes P, Chen G, Chen H, Chillotti C, Clark SR, Colom F, Cousins DA, Cruceanu C, Czerski PM, Dayer A, Etain B, Falkai P, Frisén L, Gard S, Garnham JS, Goes FS, Grof P, Gruber O, Hashimoto R, Hauser J, Herms S, Jamain S, Jiménez E, Kahn J, Kassem L, Kittel-Schneider S, Kliwicki S, König B, Kusumi I, Lackner N, Laje G, Landén M, Lavebratt C, Leboyer M, Leckband SG, López Jaramillo CA, MacQueen G,	IMPACT FACTOR 3.532	Perzentil -

	Manchia M, Martinsson L, Mattheisen M, McCarthy MJ, McElroy SL, Mitjans M, Mondimore FM, Monteleone P, Nievergelt CM, Ösby U, Ozaki N, Perlis RH, Pfennig A, Reich-Erkelenz D, Rouleau AG, Schofield PR, Schubert KO, Schweizer BW, Seemüller F, Severino G, Shekhtman T, Shilling PD, Shimoda K, Simhandl C, Slaney CM, Smoller JW, Squassina A, Stamm T, Stopkova P, Tighe SK, Tortorella A, Turecki G, Volkert J, Witt SH, Wright AJ, Young LT, Zandi P, Potash JB, DePaulo JR, Bauer M, Reininghaus E, Novák T, Aubry J, Maj M, Baune BT, Mitchell PB, Vieta E, Frye MA, Rybakowski JK, Kuo P, Kato T, Grigoriu-Serbanescu M, Reif A, Del Zompo M, Bellivier F, Schalling M, Wray N, Kelsoe JR, Alda M, McMahon FJ, Schulze TG, Rietschel M, Nöthen MM, Cichon S (2018). Analysis of the influence of microRNAs in Lithium Response in Bipolar Disorder. <i>Front. Psychiatry</i> . 9:207.		
19.	Kalman JL, Papiol S, Forstner AJ, Heilbronner U, Degenhardt F, Strohmaier J, <u>Adli M</u> , Adorjan K, Akula N, Alda M, Anderson-Schmidt H, Andlauer TF, Anghelescu IG, Ardaur R, Arias B, Arolt V, Aubry JM, Backlund L, Bartholdi K, Bauer M, Baune BT, Becker T, Bellivier F, Benabarre A, Bengesser S, Bhattacharjee AK, Biernacka JM, Birner A, Brichant-Petitjean C, Budde M, Cervantes P, Chillotti C, Cichon S, Clark SR, Colom F, Comes AL, Cruceanu C, Czerski PM, Dannlowski U, Dayer A, Del Zompo M, DePaulo JR, Dietrich DE, Étain B, Ethofer T, Falkai P, Fallgatter A, Figge C, Flatau L, Folkerts H, Frisen L, Frye MA, Fullerton JM, Gade K, Gard S, Garnham JS, Goes FS, Grigoriu-Serbanescu M, Gryaznova A, Hake M, Hauser J, Herms S, Hoffmann P, Hou L, Jäger M, Jamain S, Jiménez E, Juckel G, Kahn JP, Kassem L, Kelsoe J, Kittel-Schneider S, Kliwicky S, Klohn-Sagatholislam F, Koller M, König B, Konrad C, Lackner N, Laje G, Landén M, Lang FU, Lavebratt C, Leboyer M, Leckband SG, Maj M, Manchia M, Martinsson L, McCarthy MJ, McElroy SL, McMahon FJ, Mitchell PB, Mitjans M, Mondimore FM, Monteleone P, Nieratschker V, Nievergelt CM, Novák T, Ösby U, Pfennig A, Potash JB, Reich-Erkelenz D, Reif A, Reimer J, Reininghaus E, Reitt M, Ripke S, Rouleau GA, Rybakowski JK, Schalling M, Scherk H, Schmauß M, Schofield PR, Schubert KO, Schulte EC, Schulz S, Senner F, Severino G, Shekhtman T, Shilling PD, Simhandl C, Slaney CM, Spitzer C, Squassina A, Stamm T, Stegmaier S, Stierl S, Stopkova P, Thiel A, Tighe SK, Tortorella A, Turecki G, Vieta E, Veeh J, von Hagen M, Wigand ME, Wiltfang J, Witt S, Wright A, Zandi PP, Zimmermann J, Nöthen M, Rietschel M, Schulze TG (2018). Investigating polygenic burden in age at disease onset in bipolar disorder: findings from an international multicentric study. <i>Bipolar Disord</i> . In print.	IMPACT FACTOR 4.539	Perzentil -
20.	Musil R, Seemüller F, Meyer S, Spellmann I, <u>Adli M</u> , Bauer M, Kronmüller KT, Brieger P, Laux G, Bender W, Heuser I, Fisher R, Gaebel W, Schennach R, Möller HJ, Riedel M (2018). Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder. <i>Int J Methods Psychiatr Res</i> . 27(1).	IMPACT FACTOR 3.176	Perzentil -
21.	International Consortium on Lithium Genetics (ConLi+Gen) (2018). Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study. <i>JAMA Psychiatry</i> . 75(1):65-74.	IMPACT FACTOR 15.307	Perzentil 74,2
22.	Haffner P, Quinlivan E, Fiebig J, Sondergeld LM, Strasser ES, <u>Adli M</u> , Moritz S, Stamm TJ (2018). Improving functional outcome in bipolar disorder: A pilot study on metacognitive training. <i>Clin Psychol Psychother</i> . 25(1):50-58.	IMPACT FACTOR 1.933	Perzentil -
23.	Spellmann I, Schennach R, Seemüller F, Meyer S, Musil R, Jäger M, Schmauß M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Bauer M, <u>Adli M</u> , Zeiler J, Bender W, Kronmüller KT, Ising M, Brieger P, Maier W, Lemke MR, Rütther E, Klingberg S, Gastpar	IMPACT FACTOR 4.113	Perzentil 2

	M, Riedel M, Möller HJ (2016). Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies. <i>Eur Arch Psychiatry Clin Neurosci.</i> 267(4):303-313.		
24.	Strasser ES, Haffner P, Fiebig J, Quinlivan E, Adli M, Stamm TJ (2016). Behavioral measures and self-report of impulsivity in bipolar disorder: no association between Stroop test and Barratt Impulsiveness Scale. <i>Int J Bipolar Disord.</i> 4(1):16.	IMPACT FACTOR 4.880	Perzentil 43,7
25.	The International Consortium on Lithium Genetics (ConLiGen)(2016). Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. <i>Hum Mol Genet.</i> 25(15):3383-3394.	IMPACT FACTOR 5.985	Perzentil 92,8
26.	Seemüller F, Obermeier M, Schennach R, Bauer M, Adli M, Brieger P, Laux G, Riedel M, Falkai P, Möller HJ (2016). Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients. <i>BMC Psychiatry.</i> 16:153.	IMPACT FACTOR 2.210	Perzentil 26,7
27.	Hasselmann H, Bellmann-Strobl J, Ricken R, Oberwahrenbrock T, Rose M, Otte C, Adli M, Paul F, Brandt AU, Finke C, Gold SM (2016). Characterizing the phenotype of multiple sclerosis – associated depression in comparison with idiopathic major depression. <i>Mult Scler.</i> 22(11):1476-1484.	IMPACT FACTOR 4.82	Perzentil 77,7
28.	Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N, Ardaur R, Arias B, Backlund L, Banzato CEM, Benabarre A, Bengesser S, Bhattacharjee AK, Biernacka JM, Birner A, Brichant-Petitjean C, Bui ET, Cervantes P, Chen GB, Chen HC, Chillotti C, Cichon S, Clark SR, Colom F, Cousins DA, Cruceanu C, Czerski PM, Dantas CR, Dayer A, Étain B, Falkai P, Forstner AJ, Frisé L, Fullerton JM, Gard S, Garnham JS, Goes FS, Grof P, Gruber O, Hashimoto R, Hauser J, Herms S, Hoffmann P, Hofmann A, Jamain S, Jiménez E, Kahn JP, Kassem L, Kittel-Schneider S, Kliwicki S, König B, Kusumi I, Lackner N, Laje G, Landén M, Lavebratt C, Leboyer M, Leckband SG, Jaramillo CAL, MacQueen G, Manchia M, Martinsson L, Mattheisen M, McCarthy MJ, McElroy SL, Mitjans M, Mondimore FM, Monteleone P, Nievergelt CM, Nöthen MM, Ösby U, Ozaki N, Perlis RH, Pfennig A, Reich-Erkelenz D, Rouleau GA, Schofield PR, Schubert KO, Schweizer BW, Seemüller F, Severino G, Shekhtman T, Shilling PD, Shimoda K, Simhandl C, Slaney CM, Smoller JW, Squassina A, Stamm T, Stopkova P, Tighe SK, Tortorella A, Turecki G, Volkert J, Witt S, Wright A, Young LT, Zandi PP, Potash JB, DePaulo JR, Bauer M, Reininghaus EZ, Novák T, Aubry JM, Maj M, Baune BT, Mitchell PB, Vieta E, Frye MA, Rybakowski JK, Kuo PH, Kato T, Grigoriu-Serbanescu M, Reif A, Del Zompo M, Bellivier F, Schalling M, Wray NR, Kelsoe JR, Alda M, Rietschel M, McMahon FJ, Schulze TG (2016). Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. <i>Lancet.</i> 387(10023):1085-1093.	IMPACT FACTOR 39.207	Perzentil 97,2
29.	Bauer M, Berman S, Stamm T, Plotkin M, Adli M, Pilhatsch M, London ED, Helleman GS, Whybrow PC, Schlagenaus F (2016). Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo-controlled positron emission tomography study. <i>Mol Psychiatry.</i> 21(2):229-36.	IMPACT FACTOR 5.620	Perzentil 83,6
30.	Willert A, Mohnke S, Erk S, Schnell K, Romanczuk-Seiferth N, Krusche E, Schreiter S, Spengler S, Herold D, Wackerhagen C, Pöhlend L, Garbusow M, Stamm T, Adli M, Heinz A, BERPohl F, Walter H. (2015). Alterations in neural Theory of Mind processing in euthymic patients with bipolar disorder and unaffected relatives. <i>Bipolar Disorders.</i> 17(8):880-91	IMPACT FACTOR 4.888	Perzentil 7,3
31.	Seemüller F, Meier S, Obermeier M, Musil R, Bauer M, Adli M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Riedel M, Falkai P, Möller HJ (2014). Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe	IMPACT FACTOR 3.355	Perzentil 74,4

	relapse rates and risk factors. <i>Eur Arch Psychiatry Clin Neurosci.</i> 264(7): 567-75.		
32.	Stamm TJ, Lewitzka U, Sauer C, Pilhatsch M, Smolka MN, Koeberle U, Adli M, Ricken R, Scherk H, Frye MA, Juckel G, Assion HJ, Gitlin M, Whybrow PC, Bauer M (2014). Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study. <i>J Clin Psychiatry.</i> 75(2): 162-8.	IMPACT FACTOR 3.761	Perzentil 61,9
33.	Rentzsch J, Adli M, Wiethoff K, Gómez-Carrillo de Castro A, Gallinat J (2014). Pretreatment anterior cingulate activity predicts antidepressant treatment response in major depressive episodes. <i>Eur Arch Psychiatry Clin Neurosci.</i> 264(3): 213-23.	IMPACT FACTOR 3.525	Perzentil 56,9
34.	Manchia M, Adli M, Akula N, Ardu R, Aubry JM, Backlund L, Banzato CE, Baune BT, Bellivier F, Bengesser S, Biernacka JM, Brichant-Petitjean C, Bui E, Calkin CV, Cheng AT, Chillotti C, Cichon S, Clark S, Czerski PM, Dantas C, Zompo MD, Depaulo JR, Detera-Wadleigh SD, Etain B, Falkai P, Frisé L, Frye MA, Fullerton J, Gard S, Garnham J, Goes FS, Grof P, Gruber O, Hashimoto R, Hauser J, Heilbronner U, Hoban R, Hou L, Jamain S, Kahn JP, Kassem L, Kato T, Kelsoe JR, Kittel-Schneider S, Kliwiczki S, Kuo PH, Kusumi I, Laje G, Lavebratt C, Leboyer M, Leckband SG, López Jaramillo CA, Maj M, Malafosse A, Martinsson L, Masui T, Mitchell PB, Mondimore F, Monteleone P, Nallet A, Neuner M, Novák T, O'Donovan C, Osby U, Ozaki N, Perlis RH, Pfennig A, Potash JB, Reich-Erkelenz D, Reif A, Reininghaus E, Richardson S, Rouleau GA, Rybakowski JK, Schalling M, Schofield PR, Schubert OK, Schweizer B, Seemüller F, Grigoriu-Serbanescu M, Severino G, Seymour LR, Slaney C, Smoller JW, Squassina A, Stamm T, Steele J, Stopkova P, Tighe SK, Tortorella A, Turecki G, Wray NR, Wright A, Zandi PP, Zilles D, Bauer M, Rietschel M, McMahon FJ, Schulze TG, Alda M (2013). Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. <i>PLoS One.</i> 8(6):e65636	IMPACT FACTOR 3.530	Perzentil 85,6
35.	Berghöfer A, Alda M, Adli M, Baethge C, Bauer M, Bschor T, Grof P, Müller-Oerlinghausen B, Rybakowski JK, Suwalska A, Pfennig A (2013). Stability of lithium treatment in bipolar disorder - long-term follow-up of 346 patients. <i>Int J Bipolar Disord.</i> 1:11.		Perzentil 49,2
36.	Rhein C, Naumann J, Mühle C, Zill P, Adli M, Hegerl U, Hiemke C, Mergl R, Möller HJ, Reichel M, Kornhuber J (2013). The Acid Sphingomyelinase Sequence Variant p.A487V Is Not Associated With Decreased Levels of Enzymatic Activity. <i>JIMD Rep.</i> 8:1-6	IMPACT FACTOR 4.138	Perzentil 9,2
37.	Musil R, Zill P, Seemüller F, Bondy B, Meyer S, Spellmann I, Bender W, Adli M, Heuser I, Fisher R, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Möller HJ, Riedel M (2013). Genetics of emergent suicidality during antidepressive treatment--data from a naturalistic study on a large sample of inpatients with a major depressive episode. <i>Eur Neuropsychopharmacol.</i> 23(7): 663-74.	IMPACT FACTOR 4.736	Perzentil 42,4
38.	Musil R, Zill P, Seemüller F, Bondy B, Obermeier M, Spellmann I, Bender W, Adli M, Heuser I, Zeiler J, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Möller HJ, Riedel M (2013). No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. <i>Eur Arch Psychiatry Clin Neurosci.</i> 263(5):405-12.	IMPACT FACTOR 3.355	Perzentil 44,5
39.	Lange C, Adli M, Zschucke E, Beyer R, Ising M, Uhr M, Birmphohl F (2012). Affective set-shifting deficits in patients with major depression in remission. <i>J Psychiatr Res.</i> 46(12):1623-6.	IMPACT FACTOR 4.460	Perzentil 28,4
40.	Stoy M, Schlagenhaut F, Sterzer P, Birmphohl F, Hägele C, Suchotzki K, Schmack K, Wrase J, Ricken R, Knutson B, Adli M, Bauer M, Heinz A,	IMPACT FACTOR	Perzentil

	Ströhle A (2012). Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram. <i>J Psychopharmacol.</i> 26:677-688.	3.396	95
41.	Ricken R, Bermpohl F, Schlattmann P, Bschor T, Adli M, Mönter N, Bauer M (2012). Long-term treatment with supraphysiological doses of thyroid hormone in affective disorders - effects on bone mineral density. <i>J Affect Disord.</i> 136: 89-94.	IMPACT FACTOR 3.740	Perzentil 35,7
42.	Seemüller F, Riedel M, Obermeier M, Schennach-Wolff R, Spellmann I, Meyer S, Bauer M, Adli M, Kronmüller K, Ising M, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Möller HJ (2012). The validity of self-rated psychotic symptoms in depressed inpatients. <i>Eur Psychiatry.</i> 27(7): 547-52.	IMPACT FACTOR 3.08	Perzentil 45,6
43.	Riedel M, Möller HJ, Obermeier M, Adli M, Bauer M, Kronmüller K, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Schennach-Wolff R, Henkel V, Seemüller F (2011). Clinical predictors of response and remission in inpatients with depressive syndromes. <i>J Affect Disord.</i> 133:137-49.	IMPACT FACTOR 3.383	Perzentil 72,5
44.	Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Riedel M, Möller HJ (2011). Relationship between baseline severity and antidepressant treatment outcome. <i>Pharmacopsychiatry.</i> 44(1): 27-32.	IMPACT FACTOR 2.317	Perzentil 35,2
45.	Riedel M, Möller HJ, Obermeier M, Schennach-Wolff R, Bauer M, Adli M, Kronmüller K, Nickel T, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Seemüller F (2010). Response and remission criteria in major depression – a validation of current practice. <i>J Psychiatr Res</i> 44: 1063-1068.	IMPACT FACTOR 4.679	Perzentil 93,0
46.	Seemüller F, Möller HJ, Obermeier M, Adli M, Bauer M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Schennach-Wolff R, Henkel V, Riedel M (2010). Do efficacy and effectiveness samples differ in antidepressant treatment outcome? an analysis of eligibility criteria in randomized controlled trials. <i>J Clin Psychiatry.</i> 71:1425-33.	IMPACT FACTOR 5.218	Perzentil 40,4

### C. Reviews:

47.	Bauer M, Rush J, Ricken R, Pilhatsch M, Adli M (2018). Algorithms for treatment of major depressive disorder: efficacy and cost-effectiveness. <i>Pharmacopsychiatry.</i> Accepted on 7 June 2018.	IMPACT FACTOR 1.765	Perzentil -
48.	Gruebner O, Rapp MA, Adli M, Kluge U, Galea S, Heinz A (2017). Cities and Mental Health. <i>Dtsch Arztebl Int.</i> 114(8):121-127.	IMPACT FACTOR 3.738	Perzentil 91,5
49.	Ricken R, Ulrich S, Schlattmann P, Adli M (2017). Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression. <i>Eur Neuropsychopharmacol.</i> 27(8):714-731.	IMPACT FACTOR 4.577	Perzentil 65,2
50.	Ulrich S, Ricken R, Adli M (2017). Tranylcypromine in mind (Part I): Review of pharmacology. <i>Eur Neuropsychopharmacol.</i> 27(8):697-713.	IMPACT FACTOR 4.577	Perzentil 81,7
51.	Holzinger F, Fahrenkrog S, Roll S, Kleefeld F, Adli M, Heintze C (2017). Discharge management strategies and post-discharge care interventions for depression - Systematic review and meta-analysis. <i>J Affect Disord.</i> 223:82-94.	IMPACT FACTOR 3.845	Perzentil 38,1
52.	Köhler S, Cierpinsky K, Kronenberg G, Adli M (2016). The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. <i>J Psychopharmacol.</i> 30(1):13-22.	IMPACT FACTOR 3.898	Perzentil 95,1
53.	Borgmann M, Holtkamp M, Adli M, Behr J (2016). Depression and epilepsy: Two clinical pictures with common causes? <i>Nervenarzt.</i> 87(7):724-30.	IMPACT FACTOR 0.787	Perzentil 13

54.	Bauer M, <u>Adli M</u> , Ricken R, Severus E, Pilhatsch M (2014). Role of lithium augmentation in the management of major depressive disorder. <i>CNS Drugs</i> . 28(4): 331-42.	IMPACT FACTOR 4.376	Perzentil 85,4
55.	Bschor T, Bauer M, <u>Adli M</u> (2014). Chronic and treatment resistant depression — diagnosis and stepwise therapy. <i>Dtsch Arztebl Int</i> . 111(45): 766-76.	IMPACT FACTOR 3.608	Perzentil 87,4
56.	Krings-Ernst I, Ulrich S, <u>Adli M</u> (2013). Antidepressant treatment with MAO-inhibitors during general and regional anesthesia: a review and case report of spinal anesthesia for lower extremity surgery without discontinuation of tranlycypromine. <i>Int J Clin Pharmacol Ther</i> . 51(10): 763-70.	IMPACT FACTOR 1.200	Perzentil 8,5
57.	Köhler S, Bauer M, <u>Adli M</u> (2012). Behandlungsstrategien der therapieresistenten Depression. <i>Psychiatrie und Psychotherapie up2date</i> . 6: 137-148.		Perzentil -
58.	Rentzsch, J, Ricken R, <u>Adli M</u> (2011). Akutbehandlung der Manie. <i>Psychiatrie und Psychotherapie up2date</i> . 5: 209-224.		Perzentil -

#### D. Comments and Letters:

59.	<u>Adli M</u> , Berger M, Brakemeier EL, Engel L, Fingerhut J, Gomez-Carrillo A, Hehl R, Heinz A, HJM, Mehran N, Tolaas S, Walter H, Weiland U, Stollmann J (2017). Neurourbanism: towards a new discipline. <i>Lancet Psychiatry</i> . 4(3):183-185.	IMPACT FACTOR 11.588	Perzentil 76,4
60.	<u>Adli M</u> , Berger M (2015). Tricyclic antidepressants for initial treatment of depressive episodes? <i>Con. Nervenarzt</i> . 87(5):561-2.	IMPACT FACTOR 0.787	Perzentil 87,4
61.	Berger M, <u>Adli M</u> , Beine KH, Bschor T, Herpertz S, Lauterbach K (2015). Psychiatrische Versorgung: Das Krankenhaus-Psych-Budget – ein Alternativkonzept. <i>Dtsch Arztebl</i> . 112(13): A 574-6.	IMPACT FACTOR 3.608	Perzentil -
62.	Bschor T, Bauer M, <u>Adli M</u> (2015). Comment on: Chronic and treatment resistant depression: diagnosis and stepwise therapy. <i>Dtsch Arztebl Int</i> . 112(24):421-2.	IMPACT FACTOR 3.608	Perzentil 27,3
63.	<u>Adli M</u> , Hegerl U. (2014). Do we underestimate the benefits of antidepressant drugs? <i>Lancet</i> . 383(9926): 1361-2.	IMPACT FACTOR 39.207	Perzentil 29,6
64.	Fakhri H*, Ricken R*, <u>Adli M*</u> , Fajol A, Walter M, Föller M, Lang F, Lang UE, Lange C (2014). Impact of Lithium Treatment on FGF-23 Serum Concentrations in Depressive Patients. <i>J Clin Psychopharmacol</i> . 34(6): 745-7.	IMPACT FACTOR 3.761	Perzentil 6,9
65.	<u>Adli M</u> , Kleinert S, Bonk M, Wesslingh S, Ganten D (2011). From science to policy: the M8 Alliance invites policy makers to step in. <i>Lancet</i> , 378: 1447-1449.	IMPACT FACTOR 38.278	Perzentil -

#### E. Other Publications (not peer-reviewed):

66.	<u>Adli M</u> , Berger M, Brakemeier EL, Engel L, Fingerhut J, Hehl R, Heinz A, Mayer H. J, Matussek T, Mehran N, Tolaas S, Walter H, Weiland U, Sollmann J (2016). Neurourbanistik – ein methodischer Schluß zwischen Stadtplanung und Neurowissenschaften. <i>Die Psychiatrie</i> . 13(2):70-8.		Perzentil -
67.	Kiermeir J, Gassner LM, Siebörger A, Wiethoff K, Ricken R, Stamm T, Bauer M, Heinz A, <u>Adli M</u> (2012). Euthymic Therapy to Reduce Residual Symptoms		Perzentil -

of Depression and Strengthen Self-Care: a Randomised Controlled Trial. <i>German J Psychiatry</i> . 15 (1): 15-22.		
---	--	--

#### F. Editor:

<u>Adli M.</u> Stress and the City: Warum Städte uns krank machen. Und warum sie trotzdem gut für uns sind. 1. Auflage, 2017, C. Bertelsmann Verlag, München
--

Bauer M, Berghöfer A, <u>Adli M</u> (eds.) Akute und therapieresistente Depressionen. Pharmakotherapie, Psychotherapie, Innovationen. 2., vollständig neuberarbeitete Auflage 2005 (1. Auflage 1997, 1. Nachdruck 1998). Springer Verlag, Berlin, Heidelberg, New York
--

#### G. Book Chapters:

Schramm E, Bauer M, <u>Adli M.</u> Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 14. Auflage. München: Urban & Fischer S. (publication due in December 2018)
---

Schramm E, Bauer M, <u>Adli M</u> (2017). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 13. Auflage. München: Urban & Fischer S. 183-208.
--

Schramm E, Bauer M, <u>Adli M</u> (2016). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 12. Auflage. München: Urban & Fischer S. 183-208.
--

Schramm E, Bauer M, <u>Adli M</u> (2015). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 11. Auflage. München: Urban & Fischer S. 183-208.
--

Schramm E, Bauer M, <u>Adli M</u> (2014). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 10. Auflage. München: Urban & Fischer S. 183-208.
--

Schramm E, Bauer M, <u>Adli M</u> (2013). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 9. Auflage. München: Urban & Fischer S. 183-208.
---

Schramm E, Bauer M, <u>Adli M</u> (2012). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 8. Auflage. München: Urban & Fischer
---

Schramm E, Bauer M, <u>Adli M</u> (2011). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 7. Auflage. München: Urban & Fischer, S. 165-188.
--